USPTO serial 79045357
BIOMEDICA
Reviewed by CopyMark Law Group
Reg. 3643630Status 404
- Filing date
- Status date
- Registration date
- Jun 23, 2009
- Examiner
- SETTLES LEWIS, SHAILA E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BIOMEDICA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Purvi J. Patel
PURVI J. PATEL HAYNES AND BOONE, LLP2323 VICTORY AVENUESUITE 700DALLAS, TX 75219-7673Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for use in industry and science for use in gene delivery technology and the manufacture of pharmaceuticals and retroviral vector preparations; enzymes for laboratory and research use; chemical products for in vitro use in laboratories and for analysis, namely, for use in gene delivery technology, micro-organisms for laboratory and research use, cell cultures for laboratory and research use, plasmids and cultures of micro-organisms for laboratory and research use, deoxyribonucleic acid sequences for laboratory and research use, cloning vehicles, namely, chemical preparations for scientific purposes for use in biotechnology, research and development and recombinant deoxyribonucleic acid variations thereof for laboratory and research use, all for in vivo use; none of the goods in this class for medical or veterinary purposes; none of the foregoing goods including or for use in connection with the immunoassay diagnostic test devices containing reagent test strips for detecting the presence of drugs of abuse in saliva or urine specimens | SECTION 71 - CANCELLED | — |
| 005 | Gene therapy products for medical use, namely, clinical medical reagents, liposome reagents, nucleic acids, and vaccines for use in gene therapy, gene-based medicines, chemotherapeutics, and pharmaceutical preparations for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, bodily conditions associated with impaired immunosystems, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation, diseases of the nervous system, neuro-degenerative disorders, cardiac disorders, cystic fibrosis, inflammatory and auto-immune diseases; enzymes and enzyme preparations for medical purposes for use in gene delivery technologies; retroviral vector manufacturing preparations and retroviral vector preparations for medical use for gene delivery technologies; chemical products for medical use for genetic engineering and in gene therapy; none of the foregoing goods including or for use in connection with immunoassay diagnostic test devices containing reagent test strips for detecting the presence of drugs of abuse in saliva or urine specimens | SECTION 71 - CANCELLED | — |
| 010 | Instruments and apparatus for the administration of gene therapy products, namely, injection devices, syringes, scalpels, catheters, tubes for the administration of gene therapy products; surgical and medical apparatus and instruments, namely, injection devices, syringes, scalpels, catheters, tubes for medical services, none being blood circulatory apparatus and instruments, blood pumps, flow probes for blood pumps or blood circulatory devices for medical purposes | SECTION 71 - CANCELLED | — |
| 042 | Scientific and medical research in the fields of genetic engineering and gene therapy and scientific and medical development in the fields of genetic engineering and gene therapy, genetic engineering services and gene therapy and prophylaxis for the development and commercialization of therapeutic vaccines and gene-based therapies, namely, development of new technology for others in the field of biotechnology, collaboration for others with other biomedical and pharmaceutical entities for the commercialization of therapeutic vaccines and gene-based therapies; none of the foregoing services including or for use in connection with the immunoassay diagnostic test devices containing reagent test strips for detecting the presence of drugs of abuse in saliva or urine specimens | SECTION 71 - CANCELLED | — |
| 044 | Medical services | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Oxford BioMedica plc
- Other trademarks owned by Oxford BioMedica plc
- Other trademarks owned by Oxford BioMedica plc
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BIOMEDICA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 11, 2018 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Jan 11, 2018 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Feb 3, 2017 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 29, 2016 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 29, 2016 | INPC | INVALIDATION PROCESSED | — |
| Sep 29, 2016 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 29, 2016 | C71T | CANCELLED SECTION 71 | — |
| Jan 12, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 28, 2009 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 28, 2009 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 23, 2009 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 23, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 7, 2009 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 23, 2009 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 23, 2009 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 7, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 27, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 25, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 2009 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 25, 2009 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 25, 2009 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 25, 2009 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 3, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 3, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 26, 2009 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 26, 2009 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Jan 26, 2009 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jan 26, 2009 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Dec 17, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 17, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 26, 2008 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 26, 2008 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 26, 2008 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 2, 2008 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 2, 2008 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 30, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 30, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 30, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 30, 2008 | ALIE | ASSIGNED TO LIE | — |
| May 29, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 29, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2007 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 29, 2007 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 29, 2007 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 29, 2007 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 28, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 26, 2007 | NWAP | NEW APPLICATION ENTERED | — |
| Nov 22, 2007 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |